Results 1 to 10 of about 2,851 (170)
Drug and Alcohol Dependence, 1985 Nalbuphine is a potent analgesic with a low side effect and dependence profile in animals and man. Nalbuphine is distinguished from other agonist/antagonist analgesics in having greater antagonist activity and fewer behavioral effects at analgesic doses than pentazocine, butorphanol or buprenorphine.
S W Tam, W K Schmidt
exaly +4 more sources
Frontiers in Pharmacology, 2022 Objective: Propofol is the most widely administered intravenous anesthetic to induce deep sedation for gastroscopy procedures. Coadministration of nalbuphine can provide analgesia and sedation to patients experiencing visceral pain, thereby decreasing ...
Lili Tang +6 more
doaj +1 more source
Comparison of nalbuphine and sufentanil for colonoscopy: A randomized controlled trial. [PDF]
PLoS ONE, 2017 Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of nalbuphine with that of sufentanil in patients ...
Chaoyi Deng +5 more
doaj +1 more source
Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic
Molecules, 2021 Antipruritic effects of kappa opioid receptor (KOR) agonists have been shown in rodent models of acute and chronic scratching (itchlike behavior). Three KOR agonists, nalfurafine, difelikefalin, and nalbuphine, are in clinical studies for antipruritic ...
Saadet Inan, Nae J. Dun, Alan Cowan
doaj +1 more source
ED50 of Propofol Combined with Nalbuphine on the Sedative Effect in Painless Hysteroscopy
Pain and Therapy, 2021 Introduction Nalbuphine has gradually become a commonly used clinical analgesic drug for painless hysteroscopy. The aim of our study was to identify the median effective dose (ED50) of propofol combined with nalbuphine for painless hysteroscopy.
Chen Chen +4 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2019 Background Cancer pain is a debilitating disorder of human breast cancer and a primary determinant of the poor quality of life, and relieving pain is fundamental strategy in the cancer treatment.
Jiachuan Yu, Yuanyuan Luo, Qingping Wen
doaj +1 more source
Indian Journal of Anaesthesia, 2023 Background and Aims: Post-anaesthesia shivering is distressing and is observed after spinal and general anaesthesia. Nalbuphine, a partial mu-opioid receptor antagonist with kappa-opioid receptor agonist properties, has been successfully used to manage ...
Abhijit Nair +3 more
doaj +1 more source
Veterinary Medicine International, 2020 Nalbuphine is an agonist-antagonist opioid with adequate analgesic properties and few depressant effects on the respiratory system. However, there are no detailed reports available on cardiovascular effects of nalbuphine in dogs.
Marcel G. Marques +7 more
doaj +1 more source
Improving animal welfare using continuous nalbuphine infusion in a long-term rat model of sepsis
Intensive Care Medicine Experimental, 2017 Background Sepsis research relies on animal models to investigate the mechanisms of the dysregulated host response to infection. Animal welfare concerns request the use of potent analgesics for the Refinement of existing sepsis models, according to the ...
Victor Jeger +10 more
doaj +1 more source
Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI. [PDF]
PLoS ONE, 2013 Nalbuphine, an agonist-antagonist kappa-opioid, produces brief analgesia followed by enhanced pain/hyperalgesia in male postsurgical patients. However, it produces profound analgesia without pain enhancement when co-administration with low dose naloxone.
Robert Gear +7 more
doaj +1 more source